An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis

Objectives: To identify the risk factors associated with anti-tuberculosis drug-induced liver injury (AT-DILI) or abnormal living functioning from 757 patients with pulmonary tuberculosis (TB) registered at Nanshan Center for Chronic Disease Control (Nanshan CCDC), Shenzhen, Guangdong Province, Chin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tao Zhong, Yuzheng Fan, Xiao-Li Dong, Xujun Guo, Ka Hing Wong, Wing-tak Wong, Daihai He, Shengyuan Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	prescription scheme risk factor anti-tuberculosis drug-induced liver injury pulmonary tuberculosis China Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/fb184b9c4afa40ed80c22e4c225397b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb184b9c4afa40ed80c22e4c225397b8
record_format	dspace
spelling	oai:doaj.org-article:fb184b9c4afa40ed80c22e4c225397b82021-11-08T05:00:53ZAn Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis1663-981210.3389/fphar.2021.708522https://doaj.org/article/fb184b9c4afa40ed80c22e4c225397b82021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.708522/fullhttps://doaj.org/toc/1663-9812Objectives: To identify the risk factors associated with anti-tuberculosis drug-induced liver injury (AT-DILI) or abnormal living functioning from 757 patients with pulmonary tuberculosis (TB) registered at Nanshan Center for Chronic Disease Control (Nanshan CCDC), Shenzhen, Guangdong Province, China.Design and methods: We identified 757 TB patients who met our inclusion criteria by screening the Hospital Information System (HIS) at Nanshan CCDC. Next, we identified positive cases of AT-DILI or abnormal liver functioning based on results of the first-time liver function tests (LFTs) after taking anti-TB drugs. The χ2 test was used to relate the positive rate with a variety of factors. A logistic regression model was also used to identify statistically significant risk factors.Results: Of the 757 patients, the positive rate of AT-DILI or abnormal liver functioning was 37.9% (287/757). Univariate analysis revealed that the positive rate was 42.91% (212/494) for males and 28.52% (75/263) for females. The positive rate was significantly higher in males (p <0.001). Patients with an annual income of 9,231–13,845 USD had a significantly higher positive rate (67.35%; 33/49) than those with an income of 1,540–4616 USD (37.97%; 30/79) (p = 0.022). The most frequent prescription regime among positive cases was a 2 months supply of fixed dose combination Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets (Ⅱ) 450 mg) followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZE half/4FDC-HR) at 56.03% (144/257). The least frequent prescription regime was a 2 months supply of fixed dose combination Rifampin, Isoniazid and Pyrazinamide Capsules with Ethambutol independently followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZ + EMB/4FDC-HR) at 24.27% (25/103). The difference between these two different regimes was significant (p = 0.022). With an increase in the duration of medication, patients under various prescription regimes all showed a gradual increase in the positive rate of AT-DILI or abnormal liver functioning.Conclusion: We identified several risk factors for the occurrence of AT-DILI or abnormal liver functioning, including gender, annual income, prescription regime, dosage, and treatment time.Tao ZhongYuzheng FanXiao-Li DongXiao-Li DongXujun GuoKa Hing WongKa Hing WongWing-tak WongWing-tak WongDaihai HeDaihai HeShengyuan LiuFrontiers Media S.A.articleprescription schemerisk factoranti-tuberculosis drug-induced liver injurypulmonary tuberculosisChinaTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prescription scheme risk factor anti-tuberculosis drug-induced liver injury pulmonary tuberculosis China Therapeutics. Pharmacology RM1-950
spellingShingle	prescription scheme risk factor anti-tuberculosis drug-induced liver injury pulmonary tuberculosis China Therapeutics. Pharmacology RM1-950 Tao Zhong Yuzheng Fan Xiao-Li Dong Xiao-Li Dong Xujun Guo Ka Hing Wong Ka Hing Wong Wing-tak Wong Wing-tak Wong Daihai He Daihai He Shengyuan Liu An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
description	Objectives: To identify the risk factors associated with anti-tuberculosis drug-induced liver injury (AT-DILI) or abnormal living functioning from 757 patients with pulmonary tuberculosis (TB) registered at Nanshan Center for Chronic Disease Control (Nanshan CCDC), Shenzhen, Guangdong Province, China.Design and methods: We identified 757 TB patients who met our inclusion criteria by screening the Hospital Information System (HIS) at Nanshan CCDC. Next, we identified positive cases of AT-DILI or abnormal liver functioning based on results of the first-time liver function tests (LFTs) after taking anti-TB drugs. The χ2 test was used to relate the positive rate with a variety of factors. A logistic regression model was also used to identify statistically significant risk factors.Results: Of the 757 patients, the positive rate of AT-DILI or abnormal liver functioning was 37.9% (287/757). Univariate analysis revealed that the positive rate was 42.91% (212/494) for males and 28.52% (75/263) for females. The positive rate was significantly higher in males (p <0.001). Patients with an annual income of 9,231–13,845 USD had a significantly higher positive rate (67.35%; 33/49) than those with an income of 1,540–4616 USD (37.97%; 30/79) (p = 0.022). The most frequent prescription regime among positive cases was a 2 months supply of fixed dose combination Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets (Ⅱ) 450 mg) followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZE half/4FDC-HR) at 56.03% (144/257). The least frequent prescription regime was a 2 months supply of fixed dose combination Rifampin, Isoniazid and Pyrazinamide Capsules with Ethambutol independently followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZ + EMB/4FDC-HR) at 24.27% (25/103). The difference between these two different regimes was significant (p = 0.022). With an increase in the duration of medication, patients under various prescription regimes all showed a gradual increase in the positive rate of AT-DILI or abnormal liver functioning.Conclusion: We identified several risk factors for the occurrence of AT-DILI or abnormal liver functioning, including gender, annual income, prescription regime, dosage, and treatment time.
format	article
author	Tao Zhong Yuzheng Fan Xiao-Li Dong Xiao-Li Dong Xujun Guo Ka Hing Wong Ka Hing Wong Wing-tak Wong Wing-tak Wong Daihai He Daihai He Shengyuan Liu
author_facet	Tao Zhong Yuzheng Fan Xiao-Li Dong Xiao-Li Dong Xujun Guo Ka Hing Wong Ka Hing Wong Wing-tak Wong Wing-tak Wong Daihai He Daihai He Shengyuan Liu
author_sort	Tao Zhong
title	An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
title_short	An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
title_full	An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
title_fullStr	An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
title_full_unstemmed	An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
title_sort	investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/fb184b9c4afa40ed80c22e4c225397b8
work_keys_str_mv	AT taozhong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT yuzhengfan aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xiaolidong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xiaolidong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xujunguo aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT kahingwong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT kahingwong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT wingtakwong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT wingtakwong aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT daihaihe aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT daihaihe aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT shengyuanliu aninvestigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT taozhong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT yuzhengfan investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xiaolidong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xiaolidong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT xujunguo investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT kahingwong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT kahingwong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT wingtakwong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT wingtakwong investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT daihaihe investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT daihaihe investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis AT shengyuanliu investigationoftheriskfactorsassociatedwithantituberculosisdruginducedliverinjuryorabnormalliverfunctioningin757patientswithpulmonarytuberculosis
_version_	1718443059180470272

An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis

Ejemplares similares